文献速递免疫规划妇幼与学校卫生

四价HPV疫苗在中国女性中90个月随访的安全性随机双盲安慰剂对照三期试验

Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up.
PubMed 文献 · Vaccine · 2019-01-09

该随机双盲安慰剂对照三期试验纳入3006名20-45岁中国女性,按1:1接种三剂四价HPV疫苗或安慰剂,随访至90个月。结果显示疫苗组与安慰剂组不良事件、严重不良事件及妊娠结局频率总体相似,未发现疫苗相关严重不良事件,安全性良好。

要点

  • 四价HPV疫苗在中国20-45岁女性中耐受性良好,安全性特征与全球试验一致。
  • 疫苗组注射部位不良事件 solicited 频率高于安慰剂组(37.6% vs 27.8%)。
  • 两组严重不良事件频率相似,且均未被认为与疫苗相关。

核心结论

  • 四价HPV疫苗在中国20-45岁女性中耐受性良好,安全性特征与全球试验及安全性监测研究一致。

研究设计与样本

  • 随机、双盲、安慰剂对照三期临床试验,3006名20-45岁中国女性按1:1随机接受三剂四价HPV疫苗或安慰剂(第1天、第2月、第6月)。
  • 每剂接种后15天内通过疫苗接种报告卡收集注射部位和全身不良事件,整个研究期间收集严重不良事件、妊娠结局、新发医疗状况及胎儿/婴儿严重不良事件。

主要发现

  • 整个研究期间,疫苗组926名(61.8%)和安慰剂组856名(57.1%)报告不良事件。
  • 因考虑与疫苗接种相关的不良事件而中止研究接种者共4名(每组2名)。
  • 任何疫苗接种后15天内,疫苗组 solicited 注射部位不良事件频率高于安慰剂组(37.6% vs 27.8%),solicited 全身不良事件频率两组相似(46.8% vs 45.1%)。
  • 妊娠结局、胎儿/婴儿严重不良事件及新发医疗状况的频率在两组间总体相似,且在正常范围内。

临床怎么用

  • 为20-45岁中国女性接种四价HPV疫苗时,可参考本试验的安全性数据,重点关注注射部位不良事件。
  • 接种后应按照常规监测严重不良事件和妊娠结局,但本试验未发现疫苗相关严重不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A quadrivalent human papillomavirus (qHPV) vaccine (HPV6/11/16/18) has demonstrated efficacy and acceptable safety in international studies. However, these studies did not include participants from mainland China, which has a substantial burden of HPV-related disease. This is the first safety report with a follow-up period of up to 90 months from a randomized, double-blind, placebo-controlled trial of qHPV vaccine in Chinese women 20-45 years of age. METHODS: Participants were randomized 1:1 to receive three doses of qHPV vaccine or placebo (Day1, Month 2, and Month 6). Efficacy outcomes are reported elsewhere. Injection-site and systemic adverse events (AEs) were collected using vaccination report cards (VRCs) for 15 days following each vaccination. Serious AEs (SAEs), pregnancy outcomes, new medical conditions, and fetal/infant SAEs were collected during the entire study. RESULTS: Of 3006 participants randomized, AEs were reported by 926 (61.8%) qHPV vaccine recipients and 856 (57.1%) placebo recipients over the entire study. Four participants (two in each group) discontinued the study vaccination due to AEs that were considered vaccination-related. Within 15 days following any vaccination, injection-site AEs prompted for on the VRC were more frequent among qHPV vaccine recipients (37.6% vs 27.8%), and systemic AEs prompted for on the VRC were similar in frequency between qHPV vaccine and placebo groups (46.8% vs 45.1%). Thirty-eight and 43 participants reported SAEs in qHPV vaccine and placebo groups, respectively. No SAE was considered qHPV vaccine-related. Pregnancy outcomes, fetal/infant SAEs, and new medical conditions were generally similar in frequency between the qHPV vaccine and placebo groups, and within normal ranges. CONCLUSION: The qHPV vaccine was well tolerated and demonstrated a favorable safety profile in Chinese women 20-45 years of age, consistent with findings from global trials and safety surveillance studies. TRIAL REGISTRATION: clinicaltrials.gov; NCT00834106.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Chen W, Zhao Y, Xie X, et al. Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up. Vaccine. 2019. PMID: 30638797. doi:10.1016/j.vaccine.2018.12.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。